Cerebrolysin, 2 ml 10 pcs

Pharmacodynamics

Cerebrolysin contains low molecular weight biologically active neuropeptides that penetrate through the BBB and directly reach the nerve cells. The drug has an organ-specific multimodal effect on the brain, i.e. provides metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity.

Metabolic regulation: Cerebrolysin increases the efficiency of aerobic energy metabolism of the brain, improves intracellular protein synthesis in the developing and aging brain.

Neuroprotection: Cerebrolysin protects neurons from the damaging effects of lactate acidosis, prevents the formation of free radicals, increases survival and prevents neuronal death in conditions of hypoxia and ischemia, reduces the damaging neurotoxic effects of excitatory amino acids (glutamate).

Neurotrophic activity: Cerebrolysin is the only nootropic peptidergic drug with proven neurotrophic activity similar to the action of natural neural growth factors (NGF), but manifested under peripheral administration.

Functional neuromodulation: Cerebrolysin has a positive effect in cognitive disorders, on memory processes.

Pharmacokinetics

The complex composition of Cerebrolysin, the active fraction of which consists of a balanced and stable mixture of biologically active oligopeptides with total multifunctional action, does not allow the usual pharmacokinetic analysis of individual components.

Indications

Alzheimer’s disease;
dementia syndrome of various origins;
chronic cerebrovascular insufficiency;
ischemic stroke;
traumatic injuries of the brain and spinal cord;
mental retardation in children;
hyperactivity and attention deficit in children;
in complex therapy for endogenous depression resistant to antidepressants.

Pharmacological effect

Pharmacodynamics

Cerebrolysin contains low molecular weight biologically active neuropeptides that penetrate the BBB and directly enter nerve cells. The drug has an organ-specific multimodal effect on the brain, i.e. provides metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity.

Metabolic regulation: Cerebrolysin increases the efficiency of aerobic energy metabolism of the brain, improves intracellular protein synthesis in the developing and aging brain.

Neuroprotection: Cerebrolysin protects neurons from the damaging effects of lactic acidosis, prevents the formation of free radicals, increases survival and prevents neuronal death under conditions of hypoxia and ischemia, and reduces the damaging neurotoxic effect of excitatory amino acids (glutamate).

Neurotrophic Activity: Cerebrolysin is the only nootropic peptidergic drug with proven neurotrophic activity similar to that of natural neuronal growth factors (NGF), but manifested under conditions of peripheral administration.

Functional neuromodulation: Cerebrolysin has a positive effect in cases of cognitive impairment and on memory processes.

Pharmacokinetics

The complex composition of the drug Cerebrolysin, the active fraction of which consists of a balanced and stable mixture of biologically active oligopeptides with a total polyfunctional effect, does not allow for conventional pharmacokinetic analysis of individual components.

Special instructions

The compatibility of the drug has been tested and confirmed (within 24 hours at room temperature and light) with the following standard solutions for infusion:

– 0.9% sodium chloride solution (9 mg NaCl/ml);

– Ringer’s solution (Na+ – 153.98 mmol/l; Ca2+ – 2.74 mmol/l; K+ – 4.02 mmol/l; Cl− – 163.48 mmol/l).

– 5% glucose solution.

The simultaneous administration of Cerebrolysin with vitamins and drugs that improve cardiac circulation is allowed, but these drugs should not be mixed in the same syringe with Cerebrolysin. Only use a clear solution and only once.

Impact on the ability to drive vehicles and operate machinery. Clinical trials have shown that Cerebrolysin does not affect the ability to drive vehicles and use machinery.

Active ingredient

Brain peptide complex

Composition

1 ml of injection solution contains:

active substance:

Cerebrolysin concentrate (a complex of peptides obtained from pig brain) 215.2 mg,

excipients:

sodium hydroxide;

water for injections

Pregnancy

The drug is prescribed with caution in the first trimester of pregnancy and during lactation.

During pregnancy and breastfeeding, Cerebrolysin should be used only after a thorough analysis of the relationship between the positive effect of treatment and the risk associated with it.

The results of experimental studies do not give reason to believe that Cerebrolysin has a teratogenic effect or has a toxic effect on the fetus. However, similar clinical studies have not been conducted.

Contraindications

individual intolerance to the drug;
acute renal failure;
status epilepticus.

Side Effects

Reaction to administration: with excessively rapid administration, in rare cases, a feeling of heat, sweating, and dizziness may occur; in isolated cases – rapid heartbeat or arrhythmias. Therefore, the drug should be administered slowly.

From the gastrointestinal tract: rarely – loss of appetite, dyspepsia, diarrhea, constipation, nausea and vomiting.

From the central nervous system and peripheral nervous system: in rare cases, the expected effect of activation was accompanied by agitation (manifested by aggressive behavior, confusion, insomnia). There are reports of the occurrence in isolated cases (

From the immune system: extremely rarely – hypersensitivity reactions or allergic reactions, manifested by headache, pain in the neck, limbs, lower back, shortness of breath, chills and collapsing state.

Local reactions: rarely – redness of the skin, itching and burning at the injection site.

Other: extremely rare – studies have reported cases of hyperventilation, arterial hypertension, hypotension, fatigue, tremor, depression, apathy, dizziness and flu-like symptoms (cough, runny nose, respiratory tract infections).

It should be noted that some undesirable effects (excitement, arterial hypertension, arterial hypotension, lethargy, tremor, depression, apathy, dizziness, headache, shortness of breath, diarrhea, nausea) were identified during clinical trials and occurred equally in patients receiving Cerebrolysin and in patients in the placebo group.

Interaction

Taking into account the pharmacological profile of the drug Cerebrolysin, special attention should be paid to possible additive effects when co-administered with antidepressants, incl. MAO inhibitors. In such cases, it is recommended to reduce the dose of the antidepressant.

Cerebrolysin and balanced solutions of amino acids should not be mixed in the same solution for infusion.

Cerebrolysin is incompatible with solutions containing lipids and with solutions that change the pH of the medium (5–8).

Storage conditions

The drug should be stored in a place protected from light at a temperature not exceeding 25°C.

Shelf life

5 years.

Manufacturer

EVER Pharma Jena GmbH, Germany